Vivos Therapeutics (VVOS) Preferred Stock Liabilities (2019)
Vivos Therapeutics (VVOS) posted quarterly Preferred Stock Liabilities of $1.3 million for Q4 2019.
Vivos Therapeutics (VVOS) Preferred Stock Liabilities (2019) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Preferred Stock Liabilities for 1 consecutive years, with $1.3 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $1.3 million; the TTM figure through Dec 2019 stood at $1.3 million (changed N/A YoY), while the FY2019 annual figure was $1.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $1.3 million in Q4 2019 per VVOS's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $1.3 million in Q4 2019 and bottomed at $1.3 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | - |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | - |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | - |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | - |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | - |
| 10 | Vivos Therapeutics | 5.18 Mn | 3.38 Mn | 2.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 1.32 Mn |